These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
883 related articles for article (PubMed ID: 19287373)
1. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Scheid JF; Mouquet H; Feldhahn N; Seaman MS; Velinzon K; Pietzsch J; Ott RG; Anthony RM; Zebroski H; Hurley A; Phogat A; Chakrabarti B; Li Y; Connors M; Pereyra F; Walker BD; Wardemann H; Ho D; Wyatt RT; Mascola JR; Ravetch JV; Nussenzweig MC Nature; 2009 Apr; 458(7238):636-40. PubMed ID: 19287373 [TBL] [Abstract][Full Text] [Related]
2. Memory B cell antibodies to HIV-1 gp140 cloned from individuals infected with clade A and B viruses. Mouquet H; Klein F; Scheid JF; Warncke M; Pietzsch J; Oliveira TY; Velinzon K; Seaman MS; Nussenzweig MC PLoS One; 2011; 6(9):e24078. PubMed ID: 21931643 [TBL] [Abstract][Full Text] [Related]
3. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop. Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999 [TBL] [Abstract][Full Text] [Related]
4. HIV-1 neutralizing antibodies display dual recognition of the primary and coreceptor binding sites and preferential binding to fully cleaved envelope glycoproteins. Li Y; O'Dell S; Wilson R; Wu X; Schmidt SD; Hogerkorp CM; Louder MK; Longo NS; Poulsen C; Guenaga J; Chakrabarti BK; Doria-Rose N; Roederer M; Connors M; Mascola JR; Wyatt RT J Virol; 2012 Oct; 86(20):11231-41. PubMed ID: 22875963 [TBL] [Abstract][Full Text] [Related]
5. Polyclonal Broadly Neutralizing Antibody Activity Characterized by CD4 Binding Site and V3-Glycan Antibodies in a Subset of HIV-1 Virus Controllers. Nyanhete TE; Edwards RJ; LaBranche CC; Mansouri K; Eaton A; Dennison SM; Saunders KO; Goodman D; Janowska K; Spreng RL; Zhang L; Mudrak SV; Hope TJ; Hora B; Bradley T; Georgiev IS; Montefiori DC; Acharya P; Tomaras GD Front Immunol; 2021; 12():670561. PubMed ID: 35003053 [TBL] [Abstract][Full Text] [Related]
7. Evolution of cross-neutralizing antibody specificities to the CD4-BS and the carbohydrate cloak of the HIV Env in an HIV-1-infected subject. Mikell I; Stamatatos L PLoS One; 2012; 7(11):e49610. PubMed ID: 23152926 [TBL] [Abstract][Full Text] [Related]
9. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. Roben P; Moore JP; Thali M; Sodroski J; Barbas CF; Burton DR J Virol; 1994 Aug; 68(8):4821-8. PubMed ID: 7518527 [TBL] [Abstract][Full Text] [Related]
10. Structure and Recognition of a Novel HIV-1 gp120-gp41 Interface Antibody that Caused MPER Exposure through Viral Escape. Wibmer CK; Gorman J; Ozorowski G; Bhiman JN; Sheward DJ; Elliott DH; Rouelle J; Smira A; Joyce MG; Ndabambi N; Druz A; Asokan M; Burton DR; Connors M; Abdool Karim SS; Mascola JR; Robinson JE; Ward AB; Williamson C; Kwong PD; Morris L; Moore PL PLoS Pathog; 2017 Jan; 13(1):e1006074. PubMed ID: 28076415 [TBL] [Abstract][Full Text] [Related]
11. Broad and Potent Neutralizing Antibodies Recognize the Silent Face of the HIV Envelope. Schoofs T; Barnes CO; Suh-Toma N; Golijanin J; Schommers P; Gruell H; West AP; Bach F; Lee YE; Nogueira L; Georgiev IS; Bailer RT; Czartoski J; Mascola JR; Seaman MS; McElrath MJ; Doria-Rose NA; Klein F; Nussenzweig MC; Bjorkman PJ Immunity; 2019 Jun; 50(6):1513-1529.e9. PubMed ID: 31126879 [TBL] [Abstract][Full Text] [Related]
12. HIV-1 gp140 epitope recognition is influenced by immunoglobulin DH gene segment sequence. Wang Y; Kapoor P; Parks R; Silva-Sanchez A; Alam SM; Verkoczy L; Liao HX; Zhuang Y; Burrows P; Levinson M; Elgavish A; Cui X; Haynes BF; Schroeder H Immunogenetics; 2016 Feb; 68(2):145-55. PubMed ID: 26687685 [TBL] [Abstract][Full Text] [Related]
13. Immunization of rabbits with highly purified, soluble, trimeric human immunodeficiency virus type 1 envelope glycoprotein induces a vigorous B cell response and broadly cross-reactive neutralization. Quinnan GV; Onabajo O; Zhang P; Yan L; Mattapallil JJ; Zhang Z; Dong M; Lu M; Montefiori D; LaBranche C; Broder CC PLoS One; 2014; 9(5):e98060. PubMed ID: 24846288 [TBL] [Abstract][Full Text] [Related]
14. VH1-69 Utilizing Antibodies Are Capable of Mediating Non-neutralizing Fc-Mediated Effector Functions Against the Transmitted/Founder gp120. Smith SA; Burton SL; Kilembe W; Lakhi S; Karita E; Price M; Allen S; Derdeyn CA Front Immunol; 2018; 9():3163. PubMed ID: 30697215 [TBL] [Abstract][Full Text] [Related]
15. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. Binley JM; Lybarger EA; Crooks ET; Seaman MS; Gray E; Davis KL; Decker JM; Wycuff D; Harris L; Hawkins N; Wood B; Nathe C; Richman D; Tomaras GD; Bibollet-Ruche F; Robinson JE; Morris L; Shaw GM; Montefiori DC; Mascola JR J Virol; 2008 Dec; 82(23):11651-68. PubMed ID: 18815292 [TBL] [Abstract][Full Text] [Related]
16. Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women. Sacha CR; Vandergrift N; Jeffries TL; McGuire E; Fouda GG; Liebl B; Marshall DJ; Gurley TC; Stiegel L; Whitesides JF; Friedman J; Badiabo A; Foulger A; Yates NL; Tomaras GD; Kepler TB; Liao HX; Haynes BF; Moody MA; Permar SR Mucosal Immunol; 2015 Mar; 8(2):316-26. PubMed ID: 25100291 [TBL] [Abstract][Full Text] [Related]
17. Isolation and characterization of a novel neutralizing antibody targeting the CD4-binding site of HIV-1 gp120. Qiao Y; Man L; Qiu Z; Yang L; Sun Y; He Y Antiviral Res; 2016 Aug; 132():252-61. PubMed ID: 27387828 [TBL] [Abstract][Full Text] [Related]
18. Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. Mkhize NN; Durgiah R; Ashley V; Archary D; Garrett NJ; Karim QA; Karim SS; Moore PL; Yates N; Passmore JA; Tomaras GD; Morris L AIDS; 2016 Apr; 30(7):1005-14. PubMed ID: 26836790 [TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies from the sera of human immunodeficiency virus type 1-infected individuals bind to monomeric gp120 and oligomeric gp140. Stamatos NM; Mascola JR; Kalyanaraman VS; Louder MK; Frampton LM; Birx DL; VanCott TC J Virol; 1998 Dec; 72(12):9656-67. PubMed ID: 9811699 [TBL] [Abstract][Full Text] [Related]
20. Membrane bound modified form of clade B Env, JRCSF is suitable for immunogen design as it is efficiently cleaved and displays all the broadly neutralizing epitopes including V2 and C2 domain-dependent conformational epitopes. Das S; Boliar S; Mitra N; Samal S; Bansal M; Koff WC; Chakrabarti BK Retrovirology; 2016 Nov; 13(1):81. PubMed ID: 27871328 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]